164 related articles for article (PubMed ID: 7646996)
1. Differential sensitivity of CD30+ neoplastic cells to gelonin delivered by anti-CD30/anti-gelonin bispecific antibodies.
Sforzini S; Bolognesi A; Meazza R; Marciano S; Casalini P; Dürkop H; Tazzari PL; Stein H; Stirpe F; Ferrini S
Br J Haematol; 1995 Jul; 90(3):572-7. PubMed ID: 7646996
[TBL] [Abstract][Full Text] [Related]
2. Targeting of saporin to Hodgkin's lymphoma cells by anti-CD30 and anti-CD25 bispecific antibodies.
Sforzini S; de Totero D; Gaggero A; Ippoliti R; Glennie MJ; Canevari S; Stein H; Ferrini S
Br J Haematol; 1998 Sep; 102(4):1061-8. PubMed ID: 9734659
[TBL] [Abstract][Full Text] [Related]
3. Targeting of type 1 ribosome-inactivating proteins to CD30+ or CD25+ hematologic neoplasias by bispecific antibodies.
Sforzini S; Bolognesi A; Meazza R; Marciano S; Tazzari PL; Stein H; Stirpe F; Ferrini S
J Hematother; 1995 Oct; 4(5):429-32. PubMed ID: 8581380
[TBL] [Abstract][Full Text] [Related]
4. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice.
Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B
Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080
[TBL] [Abstract][Full Text] [Related]
5. CD30-antigen-specific targeting and activation of T cells via murine bispecific monoclonal antibodies against CD3 and CD28: potential use for the treatment of Hodgkin's lymphoma.
Pohl C; Denfeld R; Renner C; Jung W; Bohlen H; Sahin U; Hombach A; van Lier R; Schwonzen M; Diehl V
Int J Cancer; 1993 Jul; 54(5):820-7. PubMed ID: 7686889
[TBL] [Abstract][Full Text] [Related]
6. Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies.
French RR; Penney CA; Browning AC; Stirpe F; George AJ; Glennie MJ
Br J Cancer; 1995 May; 71(5):986-94. PubMed ID: 7734325
[TBL] [Abstract][Full Text] [Related]
7. Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation.
Tazzari PL; Bolognesi A; de Totero D; Falini B; Lemoli RM; Soria MR; Pileri S; Gobbi M; Stein H; Flenghi L
Br J Haematol; 1992 Jun; 81(2):203-11. PubMed ID: 1322690
[TBL] [Abstract][Full Text] [Related]
8. Anti-CD30 immunotoxins with native and recombinant dianthin 30.
Bolognesi A; Tazzari PL; Legname G; Olivieri F; Modena D; Conte R; Stirpe F
Cancer Immunol Immunother; 1995 Feb; 40(2):109-14. PubMed ID: 7882380
[TBL] [Abstract][Full Text] [Related]
9. Targeting of saporin to CD25-positive normal and neoplastic lymphocytes by an anti-saporin/anti-CD25 bispecific monoclonal antibody: in vitro evaluation.
Tazzari PL; Zhang S; Chen Q; Sforzini S; Bolognesi A; Stirpe F; Xie H; Moretta A; Ferrini S
Br J Cancer; 1993 Jun; 67(6):1248-53. PubMed ID: 8512810
[TBL] [Abstract][Full Text] [Related]
10. A CD16/CD30 bispecific monoclonal antibody induces lysis of Hodgkin's cells by unstimulated natural killer cells in vitro and in vivo.
Hombach A; Jung W; Pohl C; Renner C; Sahin U; Schmits R; Wolf J; Kapp U; Diehl V; Pfreundschuh M
Int J Cancer; 1993 Nov; 55(5):830-6. PubMed ID: 8244580
[TBL] [Abstract][Full Text] [Related]
11. In vitro anti-tumour activity of anti-CD80 and anti-CD86 immunotoxins containing type 1 ribosome-inactivating proteins.
Bolognesi A; Polito L; Tazzari PL; Lemoli RM; Lubelli C; Fogli M; Boon L; de Boer M; Stirpe F
Br J Haematol; 2000 Aug; 110(2):351-61. PubMed ID: 10971392
[TBL] [Abstract][Full Text] [Related]
12. Development of new ricin A-chain immunotoxins with potent anti-tumor effects against human Hodgkin cells in vitro and disseminated Hodgkin tumors in SCID mice using high-affinity monoclonal antibodies directed against the CD30 antigen.
Schnell R; Linnartz C; Katouzi AA; Schön G; Bohlen H; Horn-Lohrens O; Parwaresch RM; Lange H; Diehl V; Lemke H
Int J Cancer; 1995 Oct; 63(2):238-44. PubMed ID: 7591211
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of anti-CD30 immunotoxin (Ber-H2/saporin) in vitro and in severe combined immunodeficiency disease mice xenografted with human CD30+ anaplastic large-cell lymphoma.
Pasqualucci L; Wasik M; Teicher BA; Flenghi L; Bolognesi A; Stirpe F; Polito L; Falini B; Kadin ME
Blood; 1995 Apr; 85(8):2139-46. PubMed ID: 7718885
[TBL] [Abstract][Full Text] [Related]
14. Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin.
Falini B; Bolognesi A; Flenghi L; Tazzari PL; Broe MK; Stein H; Dürkop H; Aversa F; Corneli P; Pizzolo G
Lancet; 1992 May; 339(8803):1195-6. PubMed ID: 1349939
[TBL] [Abstract][Full Text] [Related]
15. Shedding of the soluble form of CD30 from the Hodgkin-analogous cell line L540 is strongly inhibited by a new CD30-specific antibody (Ki-4).
Horn-Lohrens O; Tiemann M; Lange H; Kobarg J; Hafner M; Hansen H; Sterry W; Parwaresch RM; Lemke H
Int J Cancer; 1995 Feb; 60(4):539-44. PubMed ID: 7530238
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the performance of anti-CD7 and anti-CD38 bispecific antibodies and immunotoxins for the delivery of saporin to a human T-cell acute lymphoblastic leukemia cell line.
Flavell DJ; Cooper S; Okayama K; Emery L; Flavell SU
Hematol Oncol; 1995; 13(4):185-200. PubMed ID: 7557895
[TBL] [Abstract][Full Text] [Related]
17. A gelonin-containing immunotoxin directed against human breast carcinoma.
Rosenblum MG; Zuckerman JE; Marks JW; Rotbein J; Allen WR
Mol Biother; 1992 Sep; 4(3):122-9. PubMed ID: 1445665
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a chimeric T-cell receptor with specificity for the Hodgkin's lymphoma-associated CD30 antigen.
Hombach A; Heuser C; Sircar R; Tillmann T; Diehl V; Pohl C; Abken H
J Immunother; 1999 Nov; 22(6):473-80. PubMed ID: 10570745
[TBL] [Abstract][Full Text] [Related]
19. Immune recruitment by bispecific antibodies for the treatment of Hodgkin disease.
da Costa L; Renner C; Hartmann F; Pfreundschuh M
Cancer Chemother Pharmacol; 2000; 46 Suppl():S33-6. PubMed ID: 10950145
[TBL] [Abstract][Full Text] [Related]
20. Anti-CD16/CD30 bispecific antibodies as possible treatment for refractory Hodgkin's disease.
Hartmann F; Renner C; Jung W; Pfreundschuh M
Leuk Lymphoma; 1998 Oct; 31(3-4):385-92. PubMed ID: 9869203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]